Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter
Professionals >> Visit The Body PROThe Body en Espanol
Home Page for TheBody.com, the Complete HIV/AIDS Resource What's New About HIV Ask the Experts About HIV HIV/AIDS Blogs Connect With Others About HIV Just Diagnosed With HIV HIV Treatment HIV Prevention Living With HIV Personal Stories of People With HIV
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

Indian Pharmaceutical Company Receives Tentative Drug Approval Under PEPFAR

From Henry J. Kaiser Family Foundation

November 1, 2010

Strides Arcolab Limited, a pharmaceutical company headquartered in Bangalore, India, on Friday announced it "has received tentative approval from the United States Food and Drug Administration for one [abbreviated] new drug application (ANDA) for fixed dose combination of Lamivudine and Zidovudine tablets 150 mg/300 mg under the expedited review provisions" of PEPFAR, PHARMABIZ.com reports. Strides Arcolab "has so far received 16 PEPFAR approvals," according to the news service (10/29). "The company supplies ARV [antiretroviral] products to global procurement agencies and this approval adds to the overall basket of medicines available," according to a Strides Arcolab press release (.pdf) (10/29).

Back to other news for November 2010


This information was reprinted from kff.org with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.




  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More on HIV Medications
More News on Combivir (AZT/3TC)
No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement